AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58.7 million on July 27, 2021. The all-stock acquisition is valued at $58.7 million and $5 million in cash for 7.1 million shares of AC Immune common stock based on a price of $8.26 per common share. The acquisition is subject to customary regulatory approval in Austria and expected to complete at the beginning of Q4 2021. Rolf Watter, Vera Naegeli, Lukas Roesler, Rebecca Schori, Michael Rohrer and Linus Zweifel of B?r & Karrer Ltd. acted as legal advisor to AC Immune SA. AC Immune SA (NasdaqGM:ACIU) completed the acquisition of Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG on October 13, 2021